• Press Releases.png

    Press Releases

Leading Global Biopharmaceutical Selects TrialMaster® EDC for CNS Drug Trials

June 09, 2015


Dennis Constantinou
OmniComm Systems, Inc.

Download Press Release

Fort Lauderdale, FL, June 9, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of electronic data capture and clinical data management technology, announces that a global biopharmaceutical company has selected TrialMaster EDC for nine clinical studies spanning several different central nervous system (CNS) drug programs.

The release of TrialMaster 4.2 was a primary reason for this biopharmaceutical company’s decision. TrialMaster 4.2 includes over 300 new innovative productivity and functionality enhancements. TrialMaster’s intuitive user interface and innovative data capture, data management and reporting functionality were important factors in the selection. Deploying studies in an efficient, timely and cost effective manner was especially important. OmniComm Systems has been engaged to perform the study builds for all nine clinical protocols – ensuring a high degree of study build quality and re-use efficiency.

“This award is further validation of the fact that the market expects EDC to continually evolve and OmniComm has yet again been rewarded for delivering the most innovative EDC system”, said Kuno van der Post PhD, SVP of business development, OmniComm. “TrialMaster was selected for fast build times, guided data entry, automated SDTM mapping and ability to manage a Risk-Based Monitoring Plan.”

Supporting Information

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,000 worldwide clinical trials. For more information, visit www.omnicomm.com.

OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.